Market instability expected from South Korea’s new pricing reform in 2026-2028
Every two years, South Korea adjusts the national health insurance (NHI) prices for existing listed products based on the actual…
Every two years, South Korea adjusts the national health insurance (NHI) prices for existing listed products based on the actual…
Growing budgetary pressure is a central theme in France as the country prepares for the publication of the government's 2026…
In this article, GlobalData investigates key reimbursement trends that reflect the current delays to patient access across the European region.…
International reference pricing (IRP), also known as external reference pricing (ERP), is one element commonly used when setting the price…
Drug manufacturers faced a variety of hurdles in 2024. Healthcare system reforms, preparation for the EU joint clinical assessments (JCAs)…
The UK Department of Health and Social Care (DHSC) has announced its anticipated 2025 headline payback rate for new medicines…
Since 2023, the pharmaceutical industry operating in Europe has faced an unprecedented challenge related to drug shortages. Previously, shortages were…
PD-1 inhibitors have become a paramount achievement in the oncology space and have revolutionised cancer treatment over the last decade.…
In December 2023, Vertex (US) and CRISPR Therapeutics’s (Switzerland and US) Casgevy (exagamglogene autotemcel) was approved in the US for…
Since the Russian invasion of Ukraine in early 2022, the Ukrainian budget has prioritised national security and defence. However, other…